Mirabegron Extended Release Tablets
|Manufacturer||Sun Pharma, India|
|Pack Size||Qty||Price Per Pill or Unit||Price||Cart|
|30 Tablet/s||US$ 0.83||US$ 25.00|
|60 Tablet/s||US$ 0.83||US$ 50.00|
|90 Tablet/s||US$ 0.83||US$ 75.00|
Mirago 25 mg is a medicine used in the management of overactive bladder. It contains the active ingredient Mirabegron, which receives approval from the US Food and Drug Administration for treating overactive bladder with symptoms of urinary incontinence, urinary frequency, and urgency. Mirabegron relaxes the urinary bladder muscles, which in turn decreases the activity of the overactive bladder. In patients with an overactive bladder, muscle contractions occur before the bladder's full expansion, causing frequent urges to urinate. Mirabegron stops sudden contractions of urinary bladder muscles, enabling control over urination. Thus, it increases the amount and volume of urine the bladder can hold.
Mirago is contraindicated in patients with previous hypersensitivity reactions to mirabegron or tablet excipients. No research studies have been conducted regarding using mirabegron during pregnancy to inform drug-related miscarriages, congenital disabilities, or adverse fetal outcomes. Use it carefully. Furthermore, the risk-benefit analysis should be considered while prescribing Mirago to nursing mothers. Inform your doctor if you are dealing with liver or kidney problems. You may be advised to adjust the dose. Also, let your health care provider know if you have any heart conditions, such as abnormal ECG or taking medicines that may cause it.
Mirabegron may interact with other antifungal drugs (itraconazole and ketoconazole), anti-psychotics (thioridazine, pimozide), antihypertensives (metoprolol, carvedilol), antacids (BREXIPIPRAZOLE), Blood thinners (warfarin), anti-allergic (chlorpheniramine), anti-depressants (desipramine), anti-arrhythmic ((digoxin, propafenone, flecainide), drugs used for the treatment of overactive bladder (fesoterodine, trospium, darifenacin, oxybutynin, tolterodine).
Mirago 25 mg is generally considered a safe and effective medicine. As per the manufacturer's labelling, cases of angioedema (hives/swelling under the skin's surface) have been reported, which can be fatal and require immediate treatment discontinuation. Mirabegron can increase blood pressure significantly, and it is not suggested for use in patients with uncontrolled hypertension. Other side effects of the medicine include headache, dizziness, constipation, and urinary tract infection. Speak to your doctor if you experience any side effects that become troublesome or persist for longer.
Mirago extended-release tablet is a once-daily orally administered medicine. It is suggested as an initial dose for patients with severe kidney or moderate liver impairment. The higher dose may be recommended for patients to take before or after consuming food if they tolerate the lower dose. Mirago 25 mg may take 4 to 8 weeks before patients' symptoms improve. For best results, please take it as advised by your healthcare provider.